Neoplastic Syndrome
10
0
0
7
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
20.0%
2 terminated out of 10 trials
77.8%
-8.7% vs benchmark
0%
0 trials in Phase 3/4
43%
3 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (10)
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face
Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants
Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
Studying Gene Expression in Samples From Younger Patients With Neuroblastoma
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer